These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38838619)

  • 1. Bromo-substituted indirubins for inhibition of protein kinase-mediated signalling involved in inflammatory mediator release in human monocytes.
    Bachmann V; Schädel P; Westhoff J; Perić M; Schömberg F; Skaltsounis AL; Höppener S; Pantsar T; Fischer D; Vilotijević I; Werz O
    Bioorg Chem; 2024 Aug; 149():107470. PubMed ID: 38838619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The indirubin derivative 6-bromoindirubin-3'-glycerol-oxime ether (6BIGOE) potently modulates inflammatory cytokine and prostaglandin release from human monocytes through GSK-3 interference.
    Czapka A; König S; Pergola C; Grune C; Vougogiannopoulou K; Skaltsounis AL; Fischer D; Werz O
    Biochem Pharmacol; 2020 Oct; 180():114170. PubMed ID: 32710971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
    Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
    J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.
    Pergola C; Gaboriaud-Kolar N; Jestädt N; König S; Kritsanida M; Schaible AM; Li H; Garscha U; Weinigel C; Barz D; Albring KF; Huber O; Skaltsounis AL; Werz O
    J Med Chem; 2014 May; 57(9):3715-23. PubMed ID: 24697244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death.
    Ribas J; Bettayeb K; Ferandin Y; Knockaert M; Garrofé-Ochoa X; Totzke F; Schächtele C; Mester J; Polychronopoulos P; Magiatis P; Skaltsounis AL; Boix J; Meijer L
    Oncogene; 2006 Oct; 25(47):6304-18. PubMed ID: 16702956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.
    Vougogiannopoulou K; Ferandin Y; Bettayeb K; Myrianthopoulos V; Lozach O; Fan Y; Johnson CH; Magiatis P; Skaltsounis AL; Mikros E; Meijer L
    J Med Chem; 2008 Oct; 51(20):6421-31. PubMed ID: 18816110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of novel 5-substituted indirubins as protein kinases inhibitors.
    Beauchard A; Ferandin Y; Frère S; Lozach O; Blairvacq M; Meijer L; Thiéry V; Besson T
    Bioorg Med Chem; 2006 Sep; 14(18):6434-43. PubMed ID: 16759872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3.
    Efstathiou A; Gaboriaud-Kolar N; Smirlis D; Myrianthopoulos V; Vougogiannopoulou K; Alexandratos A; Kritsanida M; Mikros E; Soteriadou K; Skaltsounis AL
    Parasit Vectors; 2014 May; 7():234. PubMed ID: 24886176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
    Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
    J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Indirubins in Inflammation and Associated Tumorigenesis.
    Cheng X; Merz KH
    Adv Exp Med Biol; 2016; 929():269-290. PubMed ID: 27771929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSK-3-selective inhibitors derived from Tyrian purple indirubins.
    Meijer L; Skaltsounis AL; Magiatis P; Polychronopoulos P; Knockaert M; Leost M; Ryan XP; Vonica CA; Brivanlou A; Dajani R; Crovace C; Tarricone C; Musacchio A; Roe SM; Pearl L; Greengard P
    Chem Biol; 2003 Dec; 10(12):1255-66. PubMed ID: 14700633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
    Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Tyrian purple to kinase modulators: naturally halogenated indirubins and synthetic analogues.
    Vougogiannopoulou K; Skaltsounis AL
    Planta Med; 2012 Sep; 78(14):1515-28. PubMed ID: 22972384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of Coumarin Derivatives as Versatile Scaffolds for GSK-3β Enzyme Inhibition.
    Francisco CS; Javarini CL; de S Barcelos I; Morais PAB; de Paula H; de S Borges W; Neto ÁC; Lacerda V
    Curr Top Med Chem; 2020; 20(2):153-160. PubMed ID: 31648640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug delivery of 6-bromoindirubin-3'-glycerol-oxime ether employing poly(D,L-lactide-co-glycolide)-based nanoencapsulation techniques with sustainable solvents.
    Czapka A; Grune C; Schädel P; Bachmann V; Scheuer K; Dirauf M; Weber C; Skaltsounis AL; Jandt KD; Schubert US; Fischer D; Werz O
    J Nanobiotechnology; 2022 Jan; 20(1):5. PubMed ID: 34983538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
    Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
    J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis.
    Xingi E; Smirlis D; Myrianthopoulos V; Magiatis P; Grant KM; Meijer L; Mikros E; Skaltsounis AL; Soteriadou K
    Int J Parasitol; 2009 Oct; 39(12):1289-303. PubMed ID: 19445946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
    Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
    Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations.
    Rivest P; Renaud M; Sanderson JT
    Chem Biol Interact; 2011 Feb; 189(3):177-85. PubMed ID: 21111724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor.
    Nisha CM; Kumar A; Vimal A; Bai BM; Pal D; Kumar A
    J Mol Graph Model; 2016 Apr; 65():100-7. PubMed ID: 26967552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.